When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in a study assessing Japanese patients with different subtypes of neovascular ...

The 5 products are 1-5: Yesafili (aflibercept-jbvf) in May 2024 Opuviz (aflibercept-yszy) in May 2024 Ahzantive (aflibercept-mrbb) in July 2024 Enzeevu (aflibercept-abzv) in August 2024 Pavblu ...

MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilarsLeading in home market ...

In 2024, the FDA approved biosimilar versions of Eylea, including the brand names Ahzantive, Enzeevu, Pavblu, Opuviz, and Yesafili. Anti-VEGF Treatments in the Pipeline In addition to injections, ...

As 2025 begins, we would like to reflect on last year’s regulatory developments in the biologics and biosimilars space. Here are some of the top regulatory developments from 2024. To close out ...